US Patent 10653753 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Patent 10653753 was granted and assigned to Eiger BioPharmaceuticals on May, 2020 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
March 3, 2017
Date of Patent
May 19, 2020
Patent Applicant
Patent Application Number
16081578
Patent Citations Received
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 10653753 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
